KR20230024378A - 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 - Google Patents

5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 Download PDF

Info

Publication number
KR20230024378A
KR20230024378A KR1020237001336A KR20237001336A KR20230024378A KR 20230024378 A KR20230024378 A KR 20230024378A KR 1020237001336 A KR1020237001336 A KR 1020237001336A KR 20237001336 A KR20237001336 A KR 20237001336A KR 20230024378 A KR20230024378 A KR 20230024378A
Authority
KR
South Korea
Prior art keywords
5meodmt
benzoate
composition
pattern
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237001336A
Other languages
English (en)
Korean (ko)
Inventor
코스모 페일딩-멜렌
티모시 메이슨
Original Assignee
벡클리 싸이테크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008968.6A external-priority patent/GB202008968D0/en
Priority claimed from GBGB2008961.1A external-priority patent/GB202008961D0/en
Priority claimed from GBGB2008964.5A external-priority patent/GB202008964D0/en
Priority claimed from GBGB2101640.7A external-priority patent/GB202101640D0/en
Priority claimed from GBGB2101634.0A external-priority patent/GB202101634D0/en
Priority claimed from GBGB2102095.3A external-priority patent/GB202102095D0/en
Priority claimed from GBGB2102100.1A external-priority patent/GB202102100D0/en
Priority claimed from GBGB2105049.7A external-priority patent/GB202105049D0/en
Priority claimed from GBGB2105047.1A external-priority patent/GB202105047D0/en
Priority claimed from GBGB2105462.2A external-priority patent/GB202105462D0/en
Application filed by 벡클리 싸이테크 리미티드 filed Critical 벡클리 싸이테크 리미티드
Publication of KR20230024378A publication Critical patent/KR20230024378A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237001336A 2020-06-12 2021-06-14 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 Pending KR20230024378A (ko)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
GB2008961.1 2020-06-12
GB2008964.5 2020-06-12
GBGB2008964.5A GB202008964D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GB2008968.6 2020-06-12
GBGB2008968.6A GB202008968D0 (en) 2020-06-12 2020-06-12 Phamaceutical composition
GBGB2008961.1A GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GB2019241.5A GB2596884B8 (en) 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
GB2019241.5 2020-12-07
GB2101640.7 2021-02-05
GBGB2101634.0A GB202101634D0 (en) 2021-02-05 2021-02-05 Pharmaceutical composition
GB2101634.0 2021-02-05
GBGB2101640.7A GB202101640D0 (en) 2021-02-05 2021-02-05 Pharmaceutical composition
GBGB2102095.3A GB202102095D0 (en) 2021-02-15 2021-02-15 Pharmaceutical composition
GB2102095.3 2021-02-15
GB2102100.1 2021-02-15
GBGB2102100.1A GB202102100D0 (en) 2021-02-15 2021-02-15 Pharmaceutical composition
GB2105047.1 2021-04-08
GBGB2105049.7A GB202105049D0 (en) 2021-04-08 2021-04-08 Pharmaceutical composition
GBGB2105047.1A GB202105047D0 (en) 2021-04-08 2021-04-08 Pharmaceutical composition
GB2105049.7 2021-04-08
GB2105462.2 2021-04-16
GBGB2105462.2A GB202105462D0 (en) 2021-04-16 2021-04-16 Pharmaceutical composition
PCT/GB2021/051475 WO2021250434A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine

Publications (1)

Publication Number Publication Date
KR20230024378A true KR20230024378A (ko) 2023-02-20

Family

ID=76641719

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001336A Pending KR20230024378A (ko) 2020-06-12 2021-06-14 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물

Country Status (14)

Country Link
US (6) US11518742B2 (https=)
EP (5) EP4279070B1 (https=)
JP (2) JP7795482B2 (https=)
KR (1) KR20230024378A (https=)
CN (2) CN119613319A (https=)
AU (1) AU2021289147A1 (https=)
BR (1) BR112022025306A2 (https=)
CA (1) CA3187020A1 (https=)
DK (1) DK4279070T3 (https=)
ES (1) ES3007386T3 (https=)
FI (1) FI4279070T3 (https=)
IL (1) IL298871A (https=)
NZ (1) NZ795865A (https=)
WO (2) WO2021250435A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
JP2024520017A (ja) * 2021-05-26 2024-05-21 マインドセット ファーマ インコーポレイテッド 幻覚剤と脂肪酸との併用
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
KR20240132439A (ko) 2021-07-22 2024-09-03 지에이치 리서치 아일랜드 리미티드 트립타민 유도체의 제조 방법
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4408412A4 (en) * 2021-09-30 2025-07-16 ATAI Life Sciences AG COMPOSITIONS AND METHODS FOR TREATING HEADACHES
EP4159192A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
AU2022413759A1 (en) * 2021-12-13 2024-06-27 Beckley Psytech Limited Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023137094A1 (en) * 2022-01-12 2023-07-20 Eleusis Therapeutics Us, Inc. Psilocin benzoate formulation for intravenous infusion
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
PT4313945T (pt) 2022-03-27 2024-06-11 Gh Res Ireland Limited Sal de hidrobrometo cristalino de 5-meo-dmt
KR20250005175A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 양극성 장애의 치료를 위한 5-meo-dtm
US20250213532A1 (en) 2022-03-27 2025-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder
US12264131B2 (en) * 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
CA3267555A1 (en) * 2022-10-26 2024-05-02 Atai Therapeutics, Inc. Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use
WO2024105379A1 (en) * 2022-11-14 2024-05-23 Beckley Psytech Limited Formulations of 5-meo-dmt
GB202306256D0 (en) 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
EP4727525A1 (en) * 2023-06-13 2026-04-22 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025024637A1 (en) * 2023-07-25 2025-01-30 Atai Therapeutics, Inc. Compositions for limiting sympathomimetic effects of psychedelic therapeutics
WO2025068714A1 (en) * 2023-09-28 2025-04-03 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
WO2025153822A1 (en) 2024-01-18 2025-07-24 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) powder formulations
WO2026068950A1 (en) * 2024-09-27 2026-04-02 Beckley Psytech Limited Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
WO2026068951A1 (en) * 2024-09-27 2026-04-02 Beckley Psytech Limited 5-methoxy-dmt for use in the treatment of depression
WO2026068953A1 (en) * 2024-09-27 2026-04-02 Beckley Psytech Limited Methods and kits comprising 5-meo-dmt for use in treating depression
WO2026078143A1 (en) * 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2774763A (en) 1956-12-18 Preparation of amides of lysergic age
US2997470A (en) 1956-03-05 1961-08-22 Lilly Co Eli Lysergic acid amides
US3078214A (en) 1958-09-12 1963-02-19 Sandoz Ag Treatment of mental disturbances with esters of indoles
GB981192A (en) 1960-03-30 1965-01-20 Westminster Bank Ltd Improvements in or relating to 4 hydroxytryptamine esters
US3224945A (en) 1963-05-06 1965-12-21 College Of Pharmacy Process for the production of ergot alkaloids
BE792515A (fr) 1971-12-10 1973-06-08 Sandoz Sa Nouveaux derives de l'acide lysergique, leur preparation et leur application comme medicaments
CH578565A5 (en) 1972-12-07 1976-08-13 Sandoz Ag N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity
HU172649B (hu) 1975-04-24 1978-11-28 Gyogyszerkutato Intezet Sposob poluchenija novykh biologicheski aktivnykh lizergamidov
GB1584464A (en) 1977-04-19 1981-02-11 Farmaceutici Italia Ergot alkaloids
EP0026899A1 (de) 1979-10-09 1981-04-15 Sandoz Ag Peptidergotalkaloide, Verfahren zu deren Herstellung, diese enthaltende pharmakologische Zusammensetzungen und ihre Anwendung bei der therapeutischen Behandlung
WO2001015677A2 (en) * 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
US20020173549A1 (en) 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
KR100523257B1 (ko) * 2000-12-29 2005-10-24 삼성전자주식회사 포지티브형 감광성 폴리이미드 전구체 및 이를 포함하는조성물
BR0312176A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
AU2007309390A1 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating Alzheimer's disease
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2010054202A2 (en) 2008-11-06 2010-05-14 Leon Rosenberg Package of pills useful for titration and method of titrating a patient
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
AU2011313814B2 (en) * 2010-10-07 2015-12-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
EP2771341A4 (en) * 2011-10-28 2015-09-23 Univ Texas NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
CN103816150A (zh) 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
CN120555529A (zh) 2018-03-08 2025-08-29 指南针探路者有限公司 生产色胺的方法
US10813116B2 (en) 2018-05-11 2020-10-20 Apple Inc. Support of advanced user equipment (UE) minimum processing times in new radio (NR) systems
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions
JP2022512230A (ja) 2018-12-14 2022-02-02 ペア セラピューティクス インコーポレイテッド ブプレノルフィン含有製品の誘導を最適化するためのデジタル治療構成要素
MD3927338T2 (ro) 2019-02-22 2025-03-31 Gh Res Ireland Limited Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale
EP4353314A3 (en) * 2019-02-22 2024-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
AU2020228289B2 (en) 2019-02-27 2026-02-05 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
EP4219498A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
GB201911024D0 (en) * 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
AU2020337903A1 (en) 2019-08-25 2022-03-31 Caamtech, Inc. Alkyl quarternary ammonium tryptamines and their therapeutic uses
JP7422473B2 (ja) 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
AU2021254855A1 (en) 2020-04-16 2022-09-15 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of psychedelics derivatives
US20210322743A1 (en) 2020-04-20 2021-10-21 Indian Institute Of Technology Bombay Microneedle array patch for drug delivery and production method thereof
IL297669A (en) 2020-05-01 2022-12-01 Emergex Usa Corp Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
IL297912A (en) 2020-05-05 2023-01-01 Univ Basel Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
CN113288883A (zh) 2021-05-24 2021-08-24 河南科技大学 一种长效缓解抑郁微针贴片及其制备方法

Also Published As

Publication number Publication date
CN119613319A (zh) 2025-03-14
US20230382858A1 (en) 2023-11-30
NZ795865A (en) 2025-12-19
US11680044B2 (en) 2023-06-20
EP4279070A3 (en) 2023-12-20
EP3941904A1 (en) 2022-01-26
US11518743B2 (en) 2022-12-06
US20220396552A1 (en) 2022-12-15
BR112022025306A2 (pt) 2023-02-28
IL298871A (en) 2023-02-01
CN116056762B (zh) 2024-12-24
JP7795482B2 (ja) 2026-01-07
US20220267267A1 (en) 2022-08-25
US11603353B2 (en) 2023-03-14
US20220259147A1 (en) 2022-08-18
EP3941583B9 (en) 2023-04-19
US20230348381A1 (en) 2023-11-02
DK4279070T3 (da) 2025-01-20
EP3941583B1 (en) 2023-02-22
US20230031944A1 (en) 2023-02-02
US11518742B2 (en) 2022-12-06
EP4483957A3 (en) 2025-03-05
CA3187020A1 (en) 2021-12-16
JP2026048894A (ja) 2026-03-17
EP3941583A1 (en) 2022-01-26
EP4595962A3 (en) 2025-10-22
EP4279070A2 (en) 2023-11-22
AU2021289147A1 (en) 2023-02-02
CN116056762A (zh) 2023-05-02
WO2021250434A1 (en) 2021-12-16
EP4595962A2 (en) 2025-08-06
JP2023530292A (ja) 2023-07-14
WO2021250435A1 (en) 2021-12-16
EP4483957A2 (en) 2025-01-01
FI4279070T3 (fi) 2025-01-02
EP4279070B1 (en) 2024-10-23
ES3007386T3 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
KR20230024378A (ko) 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물
AU2022413759A1 (en) Benzoate salt of 5-methoxy-n,n-dimethyltryptamine
JP2024054193A (ja) 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
WO2025068714A1 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
CN104394866A (zh) 用于治疗精神和行为病症的药物
US20260035334A1 (en) Method of synthesis
CN103180315A (zh) 治疗精神紊乱的方法
US20260041667A1 (en) Prescription digital therapeutics
CN120513239A (zh) 作为血清素能剂用于治疗相关病症的吲哚啉衍生物
HK40105243A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物
HK40106138A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物
HK40083780A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
FR2976179A1 (fr) Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000